Tumor regression after systemic administration of a novel tumor-targeted gene delivery system carrying a therapeutic plasmid DNA

Journal of Controlled Release

Volumn 143, Issue 2, 2010, Pages 215-221

  Koppu, Swati ^a   Oh, Yew Jinn ^a   Edrada Ebel, RuAngelie ^a   Blatchford, David R ^a   Tetley, Laurence ^b   Tate, Rothwelle J ^a   Dufès, Christine ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Cancer therapy; Gene delivery; Polypropylenimine dendrimer; Transferrin; Tumor targeting

Indexed keywords

CANCER THERAPY; GENE DELIVERY; POLYPROPYLENIMINE; POLYPROPYLENIMINE DENDRIMER; TUMOR TARGETING;

ANIMALS; BEARINGS (STRUCTURAL); DENDRIMERS; DNA; FUNCTIONAL POLYMERS; GENE EXPRESSION; GENE TRANSFER; ONCOLOGY; TUMORS;

GENE THERAPY;

DENDRIMER; PLASMID DNA; POLYPROPYLENIMINE DENDRIMER; TRANSFERRIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; DRUG TOLERABILITY; FEMALE; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PARTICLE SIZE; PRIORITY JOURNAL; SOLID TUMOR; TREATMENT DURATION; ZETA POTENTIAL;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; DENDRIMERS; DNA; FEMALE; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GLIOBLASTOMA; MICE; MICE, INBRED BALB C; PARTICLE SIZE; PLASMIDS; POLYPROPYLENES; TRANSFECTION; TRANSFERRIN; TUMOR NECROSIS FACTOR-ALPHA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77950341675     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2009.11.015     Document Type: Article

References (20)

1. Luo D., Saltzman W.M. Synthetic DNA delivery systems. Nat. Biotechnol. 2000, 18:33-37.
2. Dufès C., Keith W.N., Bisland A., Proutski I., Uchegbu I.F., Schätzlein A.G. Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors. Cancer Res. 2005, 65:8079-8084.
3. Calzolari A., Oliviero I., Deaglio S., Mariani G., Biffoni M., Sposi N.M., Malavasi F., Peschle C., Testa U. Transferrin receptor 2 is frequently expressed in human cancer cell lines. Blood Cells Mol. Dis. 2007, 39:82-91.
4. Kircheis R., Wightman L., Schreiber A., Robitza B., Rossler V., Kursa M., Wagner E. Polyethylenimine/DNA complexes shielded by transferrin target gene expression to tumors after systemic administration. Gene Ther. 2001, 8:28-40.
5. Kircheis R., Ostermann E., Wolschek M., Lichtenberger C., Magin-Lachmann C., Wightman L., Kursa M., Wagner E. Tumor-targeted gene delivery of tumor necrosis factor-α induces tumor necrosis and tumor regression without systemic toxicity. Cancer Gene Ther. 2002, 9:673-680.
6. Dufès C., Muller J.M., Couet W., Olivier J.C., Uchegbu I.F., Schätzlein A.G. Anticancer drug delivery with transferrin targeted polymeric chitosan vesicles. Pharm. Res. 2004, 21:101-107.
7. Nakase M., Inui M., Okumura K., Kamei T., Nakamura S., Tagawa T. p53 gene therapy of human osteosarcoma using a transferrin-modified cationic liposome. Mol. Cancer Ther. 2005, 4:625-631.
8. Daniels T.R., Delgado T., Helguera G., Penichet M.L. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin. Immunol. 2006, 121:159-176.
9. Hong M., Zhu S., Jiang Y., Tang G., Pei Y. Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin. J. Control. Release 2009, 133:96-102.
10. Dufès C., Schätzlein A.G., Tetley L., Gray A.I., Watson D.G., Olivier J.C., Couet W., Uchegbu I.F. Niosomes and polymeric chitosan based vesicles bearing transferrin and glucose ligands for drug targeting. Pharm. Res. 2000, 17:1250-1258.
11. Zinselmeyer B.H., Mackay S.P., Schätzlein A.G., Uchegbu I.F. The lower-generation polypropylenimine dendrimers are effective gene-transfer agents. Pharm. Res. 2002, 19:960-967.
12. Zinselmeyer B.H., Beggbie N., Uchegbu I.F., Schätzlein A.G. Quantification of beta-galactosidase activity after non-viral transfection in vivo. J. Control. Release 2003, 91:201-208.
13. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., Verweij J., Van Glabbeke M., Van Oosterom A.T., Christian M.C., Gwyther S.G. New guidelines to evaluate the response to treatment in solid tumors, European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 2000, 92:205-216.
14. Yuan F., Dellian M., Fukumura D., Leunig M., Berk D.A., Torchilin V.P., Jain R.K. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995, 55:3752-3756.
15. Dutta T., Jain N.K., McMillan N.A.J., Parekh H.S. Dendrimer nanocarriers as versatile vectors in gene delivery, Nanomedicine. NBM 2009, 10.1016/j.nano.2009.05.005.
16. Mahato R.I., Smith L.C., Rolland A. Pharmaceutical perspectives of nonviral gene therapy. Adv. Genet. 1999, 41:95-156.
17. Tros C., de Ilarduya N. Dϋzgϋneş, Efficient gene transfer by transferrin lipoplexes in the presence of serum. Biochim. Biophys. Acta 2000, 1463:333-342.
18. Kursa M., Walker G.F., Roessler V., Ogris M., Roedl W., Kircheis R., Wagner E. Novel shielded transferrin-polyethylene glycol-polyethylenimine/DNA complexes for systemic tumor-targeted gene transfer. Bioconjug. Chem. 2003, 14:222-231.
19. Kircheis R., Wightman L., Ostermann E., Wagner E. Tumor-targeted gene delivery: an attractive strategy to use highly active effector molecules in cancer treatment. Gene Ther. 2002, 9:731-735.
20. Maeda H. The tumor blood vessel as an ideal target for macromolecular anticancer agents. J. Control. Release 1992, 19:315-324.